Williamfcc (@William_fng) header
Williamfcc (@William_fng) profile picture

Strategy Lead 🧬 @bioprotocol | prev @sora_ventures @goldmansachs | Angel Investor

Taiwan
Joined February 2021
Photo by Williamfcc (@William_fng)Photo by Williamfcc (@William_fng)Photo by Williamfcc (@William_fng)Photo by Williamfcc (@William_fng)Photo by Williamfcc (@William_fng)Photo by Williamfcc (@William_fng)Photo by Williamfcc (@William_fng)Photo by Williamfcc (@William_fng)
Williamfcc retweeted
I believe the @nvidia board is not acting in the best interest of shareholders nor in a manner consistent with their fiduciary duties. What we know is that the board fired Jensen or forced his resignation for violating company policy and/or in response to the accusation of an affair with a spy. They did so without careful consideration of the impact on the company, its customers, its shareholders or other stakeholders. They rushed to judgment without the benefit of careful due diligence or even with a basic understanding of the facts. How do we know this? We know this by how quickly Jensen was fired and how little was known at the time of his firing. It takes time to convene a board meeting. There was time, maybe, for one Zoom. And this is a decision that should have been made by a board sitting in person and carefully deliberating the facts once they are known. And they should have slept on the decision and met again the day after to discuss the facts, the risks and the other implications of their decision. The timing and lack of information did not allow for careful board deliberation. While boards can fire a CEO for an inappropriate relationship with a subordinate, it should not be an automatic decision. That is why we have boards comprised of humans and not agents. A board should consider whether or not such a relationship was consensual or whether it was an abuse of power dynamics. And a board has to consider what the impact of the firing is on all stakeholders. If I were in this board, I would not have rushed to judgment based on articles in the media. I would have made sure the board had all of the facts so it could make a careful and informed decision. Boards of Delaware companies have a duty of care which means they must make informed, prudent and good faith decisions. This clearly did not happen here. What law firm is advising this board? Or is the board even taken good legal advice? It doesn’t look like it. And now the board is compounding its failures by insisting that there is no possibility for Jensen’s return as CEO. Why is it in the best interest of the company to foreclose the possibility of Jensen’s return and to do so before all of the facts are known? This is yet another breach of their duty of care. Furthermore, the board has launched an investigation whose scope is unknown. Investigations can be extremely damaging to a company and should be carefully targeted to address whatever facts need to be known rather than be overly broad in scope. In short, this looks like a series of major governance failures by directors that panicked due to headlines in the media. They likely felt compelled to do something because they were afraid of looking bad in the media, not because it was the right thing for them company. They couldn’t stand the heat. The board’s conduct here is shocking for a company of this scale and importance to our country and the world at large, particularly at this moment in history.
5,072
9,440
1,212
73,599
5,237,425
Williamfcc retweeted
NVIDIA letting Jensen go is a huge mistake, for America and for humanity. It's Apple firing Steve Jobs all over again, but much bigger, given the role of AI in defining the future of our world. I've been keeping quiet on this out of respect for Jensen's family and team, who I've met and who are amazing humans, and because I personally hate infidelity. So my heart goes out to them in this difficult personal family moment. But I can also say that Jensen is human, and makes mistakes like all of us do. Not that I matter at all, but I've known Jensen for a long time and have gotten the chance to spend a lot of time with him, behind the scenes, away from mics and cameras. I have seen him show kindness, humility, care to everyone around him, including strangers, including from the poorest most struggling parts of society, treating all the same with the same thoughtfulness and attention, because they are fellow humans and not because he has something to gain from them. That shows rare character, to maintain humility and humanity through all of it. Another data point is what people who know him well have said privately to me about Jensen over the years. I've never had anyone tell me anything but how awesome he is or how much they love him. Probably over a thousand people at this point. This includes hundreds of engineers, CEOs, colleagues, friends, etc. Also, since there was some spy talk. Jensen is as proud an American as it gets. I'm in shock frankly at all of this, including the mass hysteria around it. I love America, and I think NVIDIA letting Jensen go is terrible for America. I stand with Jensen. Love you all ❤️
4,253
8,069
999
87,087
3,943,424
He reveals deep and hidden things; he knows what lies in darkness, and light dwells with him. Daniel 2:22 Scientific singularity loading
19
4
41
3,620
Williamfcc retweeted
I got to spend all day today with Jensen in Taiwan: talking with thousands of engineers and eating street food at a night market. Jensen is received as a rockstar in Taiwan, like it's Beatles in the 60's. It's mind-blowing and fun to watch. But most importantly, through all the interactions and all my conversations with him, he remained the same humble, kind, thoughtful, funny guy he always was, even as a kid who went to these same night markets many years ago. Btw, we tried a crazy amount of different street food. It's legit some of the most delicious food I've ever had. I can't wait to share video of it, including a ton of our conversations and hangout. When I can pause for a moment from all the travel to edit the video, I'll post it. Can't wait to continue talking to Jensen and engineers at Computex this week, and exploring more of Taiwan, and of course roaming the night markets for some more delicious street food. Days like these, even more than usual, I feel like the luckiest kid in the world. Love you all! ❤️
1,169
1,290
186
27,358
1,440,948
Nearly everyone is in crypto because of the money and the 100x potential. Now, you can do 100x in stocks with real fundamentals, charts that don't jeet to 0 overnight, and have much cleaner charts/more organic moves. All while crypto chops around and continues to underperform
The issue with crypto is that it used to be a way to make outsized returns by taking outsized risk. Last cycle, the only people that really made money were memecoin scammers. The average crypto participant got wiped out on everything. Now that stocks are having their own version of alt season, crypto has lost its best use case.
25
19
2
271
44,406
Williamfcc retweeted
top 5 male experiences as a man: - first 7 figures - 6th tequila shot on a night out - random european city with two bros - first time sending your mum money - house music
96
58
5
1,539
64,064
Williamfcc retweeted
Vibe trading w/@jaeyawat Ecosystem at @BioProtocol to discuss @peptai_ (Launching today): *The Future of Peptides on-Chain* Also live on youtu.be/j7B9XHUfZbc 0:40 Intro to Bio and peptai 10:25 Nico's chemistry background take 13:25 Bio launchpad, BioXP and token use case 17:30 Reason for AI peptide discovery 20:00 Peptai raise and details 22:30 Sourcing new projects and awareness 25:30 Other Bio projects 27:50 Bio DAOs and use cases 32:00 BioXP details and closing thoughts
7
8
1
72
8,030
Ever felt like kissing a rocket? 💋🚀 1/ 🧵 2 weeks ago we stealth dropped: KISS1R-report-v1.2.pdf the latest insilico results from @peptai_ We took natural kisspeptin-10 (KP-10) and used our autonomous AI pipeline to design two ncAA-modified agonists, C1-01 and C1-02, that hit KISS1R (GPR54) with dramatically better potency and stability This is the master regulator of the entire reproductive axis. Here’s why it matters 👇
9
6
1
45
6,221
Peptide supercycle 👀
Update on the BIO Stakers Airdrop Staking BIO is the best way to secure an allocation in the PEPTAI sale. → At TGE, 20% of the total token supply will be airdropped to BIO stakers. → Staking BIO before pledging also accrues BioXP, which increases your allocation in the sale on top of the airdrop. What this means: the more you stake (and the earlier you stake), the more access you'll receive in the sale. The 14-day sale window is designed to give latecomers enough time to stake BIO, qualify for the airdrop, and accrue BioXP before TGE. Join the PEPTAI sale before it ends Thursday, May 14, 1 PM UTC: app.bio.xyz/agents/peptai
6
6
306
Gbio. Looking good here 🧬 solana:bioJ9JTqW62MLz7UKHU69gtKhPpGi1BQhccj2kmSvUJ
3
6
127
Williamfcc retweeted
A peptide era is taking shape. Join @paulkhls and the people moving the field forward in Miami. Fri, May 1 7 PM - 10 PM EDT RSVP below ↓
peptides and development is going parabolic, we’re bringing together scientists, doctors with years of experience, manufacturers and biohackers tmrw in Miami - the future of healthcare has arrived luma.com/xsi6szvh
29
9
2
115
18,497
Williamfcc retweeted
This decade belongs to science Decentralized science
This decade belongs to science
17
2
68
3,495
Williamfcc retweeted
.@peptai_ is coming. A fleet of autonomous agents for peptide drug discovery, launching on Bio. . Here’s everything you need to know 🧵↓
61
54
35
411
171,265
Williamfcc retweeted
bio protocol ($BIO) is trading at 98% off ATH while eli lilly just paid $300m for crossbridge bio, a drug candidate funded through its vitaDAO ecosystem. first nine-figure pharma acquisition of IP developed through tokenized research. pfizer is already using bio's BixBench with 59 AI agents and 1,100+ hypotheses. their agents designed a novel ADHD candidate in 24 hours for $1,500 in validation costs. clarity pumped 211% on one alzheimer's bet. bio is the launchpad that produces clarities. three new research tokens all oversubscribed with 40% demand increase. coinbase suspended futures at $0.029 which is ugly, but exchanges don't typically factor in $300m pharma exits when making listing decisions. the exit already happened. the model works. the market hasn't repriced for it.
29
14
241
45,145
Peptide supercycle. We just early.
Peptide supercycle. We just early.
1
3
232
Williamfcc retweeted
Bio Protocol designed a novel ADHD drug candidate in 24 hours using AI. First lab test: $500. Full validation: ~$1,500. Pharma spends millions and years to reach the same point. That changes what DeSci can do. Drug development has always been gated by capital, not science. Research gets funded when it aligns with commercial priorities. Plenty of valuable questions never get asked because no one with the budget chose to ask them. DeSci has been working on that gap for years, but the ambition stayed kneecapped by the cost of discovery itself. AI changes the math. With costs this low, a DAO treasury can fund a drug candidate all the way validation with real lab data. Entire categories of research pharma was NEVER going to touch are now within reach. Yet, three problems persister that AI + community funding can't clear alone: - Data inaccessibility: the training data AI needs to validate further sits locked inside pharma companies that treat it as a competitive weapon (Bio and Molecule are building to solve this via Science Beach and other initiatives) - Wet labs: even a well-characterized candidate needs physical validation on biological material. No amount of AI removes this step - Clinical trials: testing on humans still runs on the old capital structure — tens of millions to hundreds of millions. Nothing in the DeSci stack reaches that far yet DeSci gets candidates to the START of that path with something real in hand: a characterized compound with published binding data and a permanent record. That's a different conversation with pharma than a hypothesis and a pitch. There's a cultural current underneath all of this. People using AI to fight their own cancer, treat their pets, research conditions pharma deprioritized. A growing cohort motivated by personal stakes, not commercial ones. DeSci pairs cleanly with this trend, giving hope that personal motivation, not profit, can soon play a larger role in discovery.
19
61
8
306
59,251
Williamfcc retweeted
Bio was featured in @Bankless on how AI is rewriting the DeSci equation. @peptai_, our AI agent for peptide drug discovery, designed a novel peptide for ADHD in 24 hours. Wet lab validation of the peptide ran under $1,500. Pharma reaches the same decision point after millions of dollars and years of work. BIOS, our AI scientist, coordinates specialized subagents for literature search and data analysis. Built to accelerate scientific discovery. Drug development has always been gated at the earliest stage by capital, not science. Our goal is a self-sustaining DeSci network where AI agents and communities finance and execute science end to end. Bio sits at the center of this shift. Link to the article in the comments ↓
53
51
10
241
34,222
Williamfcc retweeted
Peptide drug discovery now has an autonomous pipeline. A tool takes an input and returns an output. A sequence goes in, a structure comes back. The decision of what to do with it, whether the structure is good enough, what to run next, whether the candidate advances, stays with the researcher. An agent uses tools. It evaluates the output against a defined threshold, decides whether the candidate passes or fails, and triggers the next step without waiting for a human to interpret the result. @peptai_ is built as a fleet of agents. Each agent targets a specific receptor and runs the full 9-gate pipeline: source novel candidates, calibrate the quality gates, run the computational analysis, and hand survivors to wet lab. Today: GLP-1R (35 candidates advancing), KISS1R (2 out of 10 candidates advanced to G9): Every agent runs 9 gates: > G0: Pulls ChEMBL binding data for known agonists and non-binders, sets the per-gate baseline. > G1-G3: AlphaFold and Boltz2. Structure quality, binding poses, contact conservation. > G4-G5: PRODIGY for affinity, LiteFold's MD for stability. > G6-G8: PROSPERousPlus, PlifePred, OpenSol, and ToxinPred3. Proteolytic stability, solubility, aggregation, off-target safety. > G9: Wet lab handoff with @adaptyvbio. The goal is to have synthesis paid machine-to-machine via x402. Only sequences that clear all G1 through G8 earn a synthesis recommendation. G9 is wet lab only and cannot be computationally overridden. Every gate decision is published openly on Molecule Labs. PeptAI is experimental and actively evolving. Gates, tools, and thresholds change as the pipeline learns.
28
29
10
213
40,374
We have observed heightened market volatility in $BIO We encourage all users to remain mindful of the associated risks and to exercise caution, particularly when using leveraged positions
We have observed heightened market volatility in $RAVE We encourage all users to remain mindful of the associated risks and to exercise caution, particularly when using leveraged positions
4
8
616
Williamfcc retweeted
Protein design is about to go from years to months, and the reason isn't a better model. Science software has always been specialized tools that don't talk to each other. AI made each tool smarter but the pipeline between them stayed manual. What actually changes the timeline is agents that route between all of them, pick the right tool at each step, and check outputs against a consistent benchmark before moving forward. Evaluation is the part that takes real work. Agents need context on what's already been discovered, what's genuinely new, and which hypotheses are worth testing. That's what BIOS handles. Literature synthesis, novelty analysis, hypothesis generation, all callable by any agent in the pipeline. The version that actually compresses timelines looks like agents running continuously, surfacing only candidates with strong computational scores and the right properties to survive a real lab assay, then coordinating directly with CROs and automated labs to commission experiments. The pipeline doesn't stop between steps. Nobody transfers results into the next tool.
23
15
3
127
5,153